由于原发性硬化胆道炎引起的补偿性肝硬化患者的基洛菲克索:一项开放式标签1B期研究
Cynthia Levy1,2, Stephen Caldwell3, Parvez Mantry4
1Division of Digestive Health and Liver Diseases, University of Miami Miller School of Medicine, Miami, Florida, USA.
Clinical and translational gastroenterology
|July 8, 2024
概括
选择性Farnesoid X受体激活剂Cilofexor在患有原发性硬化胆管炎相关肝硬化症的患者中表现出良好的耐受性和改善胆固醇缩标志物. 这项研究强调了 cilofexor 的优点.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 药理学 药理学是指药理学的学科.
- 胃肠病学 胃肠病学
背景情况:
- 初级硬化性胆炎 (PSC) 是一种慢性肝病,其特征是胆道炎症和阻塞,可能导致肝硬化.
- 在PSC患者中,补偿性肝硬化是一个重大挑战,因为治疗选择有限,肝脏损伤逐渐恶化.
- 目前正在研究Farnesoid X受体 (FXR) 激素因其调节胆酸代谢和减少肝炎的潜力而受到研究.
研究的目的:
- 评估选择性FXR激动剂Cilofexor的安全性和有效性,用于PSC引起的补偿性肝硬化患者.
- 在12周的治疗期内,评估Cilofexor剂量升级的耐受性.
- 探索Cilofexor对胆固醇和纤维化标志物的影响,以及胆汁酸平衡.
主要方法:
- 进行了一项概念验证,开放式标签阶段1b研究.
- 由于PSC导致的补偿性肝硬化,11名患者被纳入.
- 患者在12周内每天服用一次西洛菲克索 (30毫克,60毫克,100毫克) 的口服剂量不断升级,安全性是主要终点.
主要成果:
- 基洛菲克索一般耐受良好,是最常见的治疗出现的不良事件.
- 没有报告死亡或严重不良事件; 一名患者出现了外周,导致暂时停止治疗.
- 到第12周,胆固醇酶标记物,包括氨酸转胺酶,性酸酶和胆红素水平的显著改善.
结论:
- 在12周内增加基洛菲克索的剂量,在由于PSC引起的补偿性肝硬化患者中显示出有利的安全性.
- 基洛菲克索治疗导致关键胆固醇缩标志物显著改善,表明治疗潜力.
- 需要进一步的研究来证实这些发现,并探索PSC患者的长期疗效和安全性.
更多相关视频
06:14Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients
Published on: October 15, 2017
8.3K
07:06Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection
Published on: December 8, 2014
27.1K
相关概念视频
01:21Drugs for Treatment of Constipation-Predominant IBS
154
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
154
01:17Chronic Bowel Disorders: Introduction
439
Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
439
01:24Cystic Fibrosis: Management
154
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
Sinus disease and chronic...
154